Le Lézard
Classified in: Health
Subjects: CCA, TDS, FVT

Perrigo Company to Present at the Stifel 2017 Healthcare Conference



DUBLIN, Nov. 10, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that John T. Hendrickson, Perrigo Chief Executive Officer, will present at the 2017 Stifel Healthcare Conference at 8:45 AM EST on Tuesday, November 14, 2017.  Interested parties can access the presentation webcast at http://perrigo.investorroom.com/events-webcasts.

Perrigo Company. (PRNewsFoto/Perrigo Company)

About Perrigo 

Perrigo Company plc, a leading global healthcare company, delivers value to its customers and consumers by providing Quality Affordable Healthcare Products®. Founded in 1887 as a packager of home remedies, Perrigo has built a unique business model that is best described as the convergence of a fast-moving consumer goods company, a high-quality pharmaceutical manufacturing organization and a world-class supply chain network. Perrigo is one of the world's largest manufacturers of over-the-counter ("OTC") healthcare products and suppliers of infant formulas for the store brand market. The Company also is a leading provider of branded OTC products throughout Europe and the U.S., as well as a leading producer of "extended topical" prescription drugs. Perrigo, headquartered in Ireland, sells its products primarily in North America and Europe, as well as in other markets, including Australia, Israel and China. Visit Perrigo online at (http://www.perrigo.com).

Forward-Looking Statements

Certain statements in this press release are "forward-looking statements." These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or the negative of those terms or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control, including: the timing, amount and cost of any share repurchases; future impairment charges; the success of management transition; customer acceptance of new products; competition from other industry participants, some of whom have greater marketing resources or larger market shares in certain product categories than the Company does; pricing pressures from customers and consumers; potential third-party claims and litigation, including litigation relating to the Company's restatement of previously-filed financial information; potential impacts of ongoing or future government investigations and regulatory initiatives; resolution of uncertain tax positions; the impact of U.S. tax reform legislation; general economic conditions; fluctuations in currency exchange rates and interest rates; the consummation of announced acquisitions or dispositions, and the Company's ability to realize the desired benefits thereof; the Company's ability to achieve its guidance; and the Company's ability to execute and achieve the desired benefits of announced cost-reduction efforts and other initiatives.  In addition, the Company may identify and be unable to remediate one or more material weaknesses in its internal control over financial reporting. Furthermore, the Company and/or its subsidiaries may incur additional tax liabilities in respect of 2016 and prior years as a result of any restatement or may be found to have breached certain provisions of Irish company legislation in respect of prior financial statements and if so may incur additional expenses and penalties. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended December 31, 2016, as well as the Company's subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

 

 

SOURCE Perrigo Company plc


These press releases may also interest you

at 09:30
Frost & Sullivan's recent analysis on medical cannabis finds that the total revenue of this market in the United States is expected to grow from $5.32 billion in 2017 to $10 billion in 2022, at a compound annual growth rate (CAGR) of 13.6%. Even...

at 09:30
Imalogix, a leader in artificial intelligence process and workflow solutions, today announced the availability of the latest evolution to its platform for Diagnostic Imaging, Interventional Radiology, Cardiology, and Surgery....

at 09:30
The Sanitary Napkin for Feminine Care industry was 20,968 million USD in 2017 and is projected to reach 39,613 million USD by 2025, at a CAGR (Compounded Annual Growth Rate) of 8.28% between 2017 and 2025. The market is driven by various end-user...

at 09:29
Magnolia Health, a leading provider of health care coverage that improves care across Mississippi, recently held a comprehensive baby shower for its expecting members in the Starkville area to advance healthier pregnancies, healthier newborns and...

at 09:18
VSAT Evaluates vascular function, determines cardiovascular risks, provides prognosis of vascular diseases, objectively quantifies whether a current intervention plan is working synergistically with each patient's unique physiology, and includes...

at 09:15
Electronic Manufacturing Services, Materials Processing, Finished Products, Medical Diagnostic Devices, Monitoring & Surgical Equipments, Therapeutic Devices The global medical device contract manufacturing market was valued at $70bn in 2017....




News published on 10 november 2017 at 13:20 and distributed by: